Key result
ACE inhibitors and angiotensin receptor blockers are effective and generally well-tolerated for treating congestive heart failure and high cardiovascular risk in elderly patients up to 95 years of age.
Why the study?
Are ACE inhibitors and ARBs effective in reducing morbidity and mortality in elderly patients with heart failure or high cardiovascular risk?
Are ACE inhibitors and ARBs effective in reducing morbidity and mortality in elderly patients with heart failure or high cardiovascular risk?
This review highlights that ARBs are as effective as ACE inhibitors for heart failure and that RAS inhibition benefits high-risk cardiovascular patients, with a focus on applicability to the elderly.
Supports RAS inhibition in elderly HF/high-risk patients to age 95; leaves open need for dedicated prospective trials.
Traditionally, angiotensin converting enzyme (ACE) inhibitors have been used for the management of patients with congestive cardiac failure. Studies performed over the last decade have demonstrated that (1) angiotensin receptor blockers (ARBs) are as effective as ACE inhibitors in reducing morbidity and mortality in cardiac failure; and (2) inhibition of the renin-angiotensin system provides beneficial effects in patients at high cardiovascular risk without cardiac failure. This review focuses on the applicability of the results of the main trials with ACE inhibitors and ARBs to the elderly population.
No takes yet. Share an insight, caveat, or question.
Mangoni et al. (2006) conducted a review in Heart failure and high cardiovascular risk. ACE inhibitors and angiotensin receptor blockers vs. Placebo or active comparators was evaluated. ACE inhibitors and angiotensin receptor blockers are effective and generally well-tolerated for treating congestive heart failure and high cardiovascular risk in elderly patients up to 95 years of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: